Revance Therapeutics Enters into Amendment in Merger Agreement with Crown Laboratories

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced a significant development in its corporate actions with an amendment to its Amended and Restated Agreement and Plan of Merger. The agreement, originally dated December 7, 2024, involved Revance Therapeutics, Crown Laboratories, Inc., and Reba Merger Sub, Inc.

The recent amendment, effective December 11, 2024, clarified specific terms within the agreement, notably outlining an adjusted mechanism for calculating the Expiration Time. The agreement remains mostly intact as described in the Form 8-K filed by Revance Therapeutics on December 9, 2024. The complete documentation of this amendment, labeled Exhibit 2.1, is readily available for further reference.

This latest corporate move falls under Item 1.01 in the Form 8-K filing, encompassing the details of the A&R Merger Agreement Amendment. Moreover, under Exhibit 104 of the filing, an Interactive Data File is included with XBRL tags embedded within the Inline XBRL document.

Furthermore, in adherence to regulatory standards, Revance Therapeutics also provided disclosure in its filing regarding forward-looking statements. Stating that certain segments of their document contain forward-looking declarations that signify the company’s future financial standings, business strategies, and expectations regarding mergers and offers, they emphasized the importance of a comprehensive review of risks and uncertainties outlined in their SEC filings.

Investors and stakeholders were prompted to await the commencement of the tender offer described in the filing. The informative disclaimers made it clear that this communication did not serve as a direct offer but rather a preliminary notification. Upon initiation of the tender offer, investors were advised to diligently review all relevant documents, including the Schedule TO and Schedule 14D-9.

The filing, undersigned by Revance Therapeutics for compliance with the Securities Exchange Act of 1934, stands as a pivotal step in the company’s ongoing merger efforts. Tobin C. Schilke, Chief Financial Officer, officially signed off on behalf of Revance Therapeutics, Inc., marking December 12, 2024, as the date of this significant corporate update.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Revance Therapeutics’s 8K filing here.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.